<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409394</url>
  </required_header>
  <id_info>
    <org_study_id>TPOP1c</org_study_id>
    <nct_id>NCT02409394</nct_id>
  </id_info>
  <brief_title>Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects</brief_title>
  <official_title>Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, randomized, two-period, two-treatment (single doses of 7.5 mg hetrombopag
      fasted or fed), crossover study was conducted to evaluate the effect of a high-fat meal on
      the pharmacokinetics of hetrombopag and mass balance study in 12 healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of hetrombopag</measure>
    <time_frame>0h-120h</time_frame>
    <description>Cmax (a measure of the body's exposure to hetrombopag) will be compared under fating state and fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of hetrombopag</measure>
    <time_frame>0h-120h</time_frame>
    <description>AUC (a measure of the body's exposure to hetrombopag) will be compared under fating state and fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The accumulative excretion rate of hetrombopag and its metabolites in urine and feces</measure>
    <time_frame>0h-120h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of platelet count</measure>
    <time_frame>On day 2, 4, 6, 8,12, 14 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to Day 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>hetrombopag 7.5mg fasted to fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hetrombopag 7.5mg fed to fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <arm_group_label>hetrombopag 7.5mg fasted to fed</arm_group_label>
    <arm_group_label>hetrombopag 7.5mg fed to fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy.

          -  Weight≥50 kg，19≤BMI≤28 kg/m2.

          -  Platelet count is within normal range

        Exclusion Criteria:

          -  History of clinically significant illness.

          -  History of alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

